CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Cytarabine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02971397
NCT02971397Phase 1Completed
CompareCT.gov

Cytarabine Plus Continuous Infusion Daunorubicin Induction Therapy for Adults With Acute Myeloid Leukemia: A Feasibility Study With Cardiac MRI Monitoring

Wake Forest University Health Sciences·interventional·Posted Nov 23, 2016·Updated Mar 23, 2026

In Brief

A Phase 1 clinical trial evaluating Bone Marrow Aspiration and Biopsy, Cytarabine, and 2 other interventions for Acute Myeloid Leukemia. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This pilot clinical trial studies the side effects of cytarabine and daunorubicin hydrochloride and to see how well they work in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine and daunorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, and may be safer for the heart.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 23, 2016
Enrollment StartNov 1, 2016
Primary CompletionMar 1, 2018
Study CompletionAug 8, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.6 years ago

Interventions

Bone Marrow Aspiration and Biopsyprocedure

Undergo bone marrow aspiration and biopsy

Cytarabinedrug

Given IV

Daunorubicin Hydrochloridedrug

Given IV

Laboratory Biomarker Analysisother

Correlative studies